EUVIMEDEUVIMED entdecken
Open Access

Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer

Shahad K Alsaiari iD, Seba Nadeef, John L Daristotle iD, William Rothwell iD, Bujie Du iD, Johnny Garcia, Linzixuan Zhang iD, Morteza Sarmadi iD, Timothy A Forster, Nandita Menon, Stacey Qiaohui Lin, Lisa H Tostanoski iD und 6 weitere

Science Advances · 08.03.2024 · 10 (10)

DOI: 10.1126/sciadv.adj6380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 08.03.2024. Verfasst von Shahad K Alsaiari und 17 weiteren Autor:innen. Beteiligte Einrichtung: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: COVID-19, Zeolites. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework–8 (ZIF-8). The accumulation of ZIF-8 in endosomes and the pH-responsive release of its subunits enable selective engagement with endosomal Toll-like receptors, minimizing the risk of off-target activation. The intrinsic adjuvant properties of ZIF-8, along with the efficient delivery and biomimetic presentation of a severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain trimer, primed rapid humoral and cell-mediated immunity in a dose-sparing manner. Our study offers insights for next-generation adjuvants that can potentially impact future vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19ZeolitesHumansSARS-CoV-2Spike Glycoprotein, CoronavirusAdjuvants, ImmunologicEndosomesToll-Like Receptors

Substanzen

spike protein, SARS-CoV-2Spike Glycoprotein, CoronavirusAdjuvants, ImmunologicToll-Like ReceptorsZeolites

Autor:innen und Institutionen

  • David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

ORCID-Profile: Shahad K Alsaiari, John L Daristotle, William Rothwell, Bujie Du, Linzixuan Zhang, Morteza Sarmadi, Lisa H Tostanoski, Nicole Hachmann, Dan H Barouch, Robert Langer, Ana Jaklenec

Förderung

  • NCI NIH HHS

Zitieren

APA

Alsaiari, S. K., Nadeef, S., Daristotle, J. L., Rothwell, W., Du, B., Garcia, J., Zhang, L., Sarmadi, M., Forster, T. A., Menon, N., Lin, S. Q., Tostanoski, L. H., Hachmann, N., Wang, E. Y., Ventura, J. D., Barouch, D. H., Langer, R., & Jaklenec, A. (2024). Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer. Science Advances, 10(10). https://doi.org/10.1126/sciadv.adj6380

Vancouver

Alsaiari SK, Nadeef S, Daristotle JL, Rothwell W, Du B, Garcia J, et al. Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer. Science Advances. 2024;10(10). doi:10.1126/sciadv.adj6380

BibTeX
@article{Alsaiari2024,
  author = {Alsaiari, Shahad K and Nadeef, Seba and Daristotle, John L and Rothwell, William and Du, Bujie and Garcia, Johnny and Zhang, Linzixuan and Sarmadi, Morteza and Forster, Timothy A and Menon, Nandita and Lin, Stacey Qiaohui and Tostanoski, Lisa H and Hachmann, Nicole and Wang, Erika Yan and Ventura, John D and Barouch, Dan H and Langer, Robert and Jaklenec, Ana},
  title = {Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {10},
  doi = {10.1126/sciadv.adj6380}
}
Kostenlos starten →